{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T14:37:02Z","timestamp":1769611022945,"version":"3.49.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1016\/j.semarthrit.2003.09.010","type":"journal-article","created":{"date-parts":[[2004,4,9]],"date-time":"2004-04-09T09:21:57Z","timestamp":1081502517000},"page":"320-335","source":"Crossref","is-referenced-by-count":191,"title":["The use of interferon \u03b1 in beh\u00e7et disease: review of the literature"],"prefix":"10.1016","volume":"33","author":[{"given":"Ina","family":"K\u00f6tter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilhan","family":"G\u00fcnaydin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Zierhut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"St\u00fcbiger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2003.09.010_BIB1","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","article-title":"Beh\u00e7et\u2019s disease","volume":"341","author":"Sakane","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB2","first-page":"1078","article-title":"Criteria for diagnosis of Beh\u00e7et\u2019s disease","volume":"335","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB3","first-page":"271","article-title":"Sur un cas d\u0131\u0300ritis a hypopion r\u00e9cidivant","volume":"168","author":"Adamantiades","year":"1931","journal-title":"Ann Ocul (Paris)"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB4","first-page":"1152","article-title":"\u00dcber rezidivierende aphth\u00f6se, durch ein Virus verursachte Geschw\u00fcre am Mund, am Auge und an den Genitalien","volume":"105","author":"Beh\u00e7et","year":"1937","journal-title":"Dermatol Wochenschrift"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB5","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/0190-9622(95)91333-5","article-title":"Mucocutaneous criteria for the diagnosis of Beh\u00e7et\u2019s disease","volume":"32","author":"Jorizzo","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB6","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00000372-200010000-00001","article-title":"Histopathologic features of erythema nodosum-like lesions in Beh\u00e7et disease","volume":"22","author":"Kim","year":"2000","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB7","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1046\/j.1365-2559.2000.00859.x","article-title":"Neutrophil and endothelial cell activation in the vasa vasorum in vasculo-Beh\u00e7et disease","volume":"36","author":"Kobayashi","year":"2000","journal-title":"Histopathology"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1034\/j.1399-0039.1999.540301.x","article-title":"Beh\u00e7ets disease, the Silk Road and HLA-B51","volume":"54","author":"Verity","year":"1999","journal-title":"Tissue Antigens"},{"issue":"5 suppl 24","key":"10.1016\/j.semarthrit.2003.09.010_BIB9","first-page":"S6","article-title":"Beh\u00e7et\u2019s disease","volume":"19","author":"Gul","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB10","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/ard.60.11.996","article-title":"Beh\u00e7et\u2019s disease","volume":"60","author":"Direskeneli","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB11","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1128\/IAI.59.4.1434-1441.1991","article-title":"Association between the 65-kilodalton heat shock protein, Streptococcus sanguis, and the corresponding antibodies in Beh\u00e7et\u2019s syndrome","volume":"59","author":"Lehner","year":"1991","journal-title":"Infect Immun"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB12","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/S0140-6736(82)91268-5","article-title":"Detection of RNA complementary to herpes-simplex virus in mononuclear cells from patients with Behcet\u2019s syndrome and recurrent oral ulcers","volume":"2","author":"Eglin","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1365-2249.1990.tb05122.x","article-title":"Natural killer cell activity, interferon-gamma and antibodies to herpes viruses in patients with Behcet\u2019s disease","volume":"79","author":"Hamzaoui","year":"1990","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB14","first-page":"6","article-title":"CD4 and CD8 cell responses to herpes simplex virus in Beh\u00e7et\u2019s disease","volume":"73","author":"Young","year":"1988","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB15","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1365-2249.1990.tb05344.x","article-title":"Cytotoxic T cells against herpes simplex virus in Beh\u00e7et\u2019s disease","volume":"81","author":"Hamzaoui","year":"1990","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF02505221","article-title":"Polymerase chain reaction reveals herpes simplex virus DNA in saliva of patients with Beh\u00e7et\u2019s disease","volume":"288","author":"Lee","year":"1996","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB17","first-page":"21","article-title":"Beh\u00e7et\u2019s disease-like symptoms induced by the herpes simplex virus in ICR mice","volume":"8","author":"Sohn","year":"1998","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0923-1811(01)00086-X","article-title":"The correlation of MHC haplotype and development of Beh\u00e7et\u2019s disease-like symptoms induced by herpes simplex virus in several inbred mouse strains","volume":"26","author":"Sohn","year":"2001","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1346-8138.1994.tb01729.x","article-title":"Natural cellular cytotoxicity in Beh\u00e7et\u2019s disease","volume":"21","author":"Onder","year":"1994","journal-title":"J Dermatol"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1365-2133.1985.tb02083.x","article-title":"Natural killer cell numbers and function in peripheral lymphoid cells in Beh\u00e7et\u2019s disease","volume":"113","author":"Kaneko","year":"1985","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB21","first-page":"CD001084","article-title":"Pharmacotherapy for Beh\u00e7et\u2019s syndrome","author":"Saenz","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11926-002-0023-z","article-title":"Beh\u00e7et\u2019s disease","volume":"4","author":"Meador","year":"2002","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB23","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0021-5155(99)00029-5","article-title":"Epidemiological features and visual prognosis of Beh\u00e7et\u2019s disease","volume":"43","author":"Ando","year":"1999","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB24","first-page":"847","article-title":"A case of Beh\u00e7et\u2019s disease associated with myopathy during cyclosporin treatment","volume":"31","author":"Shibata","year":"1991","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB25","first-page":"273","article-title":"Magnetic resonance imaging of brainstem lesions in a case of neuro-Beh\u00e7et disease","volume":"49","author":"Nomura","year":"1997","journal-title":"No To Shinkei"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB26","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0161-6420(99)90120-3","article-title":"Central nervous system symptoms in patients with Beh\u00e7et disease receiving cyclosporine therapy","volume":"106","author":"Kotake","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB27","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1517\/13543784.9.9.1993","article-title":"Novel approaches to Beh\u00e7et\u2019s disease","volume":"9","author":"Sakane","year":"2000","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB28","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1098\/rspb.1957.0048","article-title":"Virus Interference","volume":"47","author":"Isaacs","year":"1957","journal-title":"Proc R Soc Ser B"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB29","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1046\/j.1365-2893.1998.00103.x","article-title":"Are all type I human interferons equivalent?","volume":"5","author":"Foster","year":"1998","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB30","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/BF00407749","article-title":"Beh\u00e7et\u2019s syndrome","volume":"278","author":"Tsambaos","year":"1986","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB31","first-page":"2371","article-title":"Crit\u00e8res propos\u00e9s pour le diagnostic de la maladie de Beh\u00e7et","volume":"36","author":"O\u2019Duffy","year":"1974","journal-title":"Rev Med"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB32","first-page":"66","article-title":"Revised diagnostic criteria for Beh\u00e7et\u2019s disease in 1987","volume":"28","author":"Mizushima","year":"1988","journal-title":"Ryumachi"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB33","first-page":"453","article-title":"Therapeutic use of alpha interferon in metastasizing malignant melanoma, disseminated Kaposi sarcoma and severe Beh\u00e7et disease","volume":"38","author":"Stadler","year":"1987","journal-title":"Hautarzt"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB34","first-page":"97","article-title":"[Beh\u00e7et disease and exogenous interferon","volume":"38","author":"Stadler","year":"1987","journal-title":"Hautarzt"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB35","first-page":"440","article-title":"Adamantiades-Beh\u00e7et disease","volume":"44","author":"Zouboulis","year":"1993","journal-title":"Hautarzt"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB36","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/art.1780360721","article-title":"Beneficial effects of interferon-alpha 2b in Beh\u00e7et\u2019s disease","volume":"36","author":"Durand","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB37","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0140-6736(94)91371-4","article-title":"Interferon-alpha 2b for refractory ocular Beh\u00e7et\u2019s disease","volume":"344","author":"Durand","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB38","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S0140-6736(94)92549-6","article-title":"Interferon-alpha 2b for refractory ocular Beh\u00e7et\u2019s disease","volume":"343","author":"Feron","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB39","first-page":"1098","article-title":"Systemic interferon alpha 2b treatment in Beh\u00e7et\u2019s syndrome","volume":"21","author":"Hamuryudan","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB40","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0190-9622(94)70226-8","article-title":"Interferon therapy for Beh\u00e7et\u2019s disease","volume":"31","author":"Alpsoy","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB41","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1056\/NEJM199502093320616","article-title":"Possible association between Beh\u00e7et\u2019s syndrome and chronic hepatitis C virus infection","volume":"332","author":"M\u00fcnke","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB42","first-page":"293","article-title":"The use of interferon alfa-2r in the treatment of autoimmune uveitis (primary or associated with Beh\u00e7et\u2019s disease)","volume":"196","author":"Sanchez Roman","year":"1996","journal-title":"Rev Clin Esp"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB43","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000246374","article-title":"Interferon alfa-2a in the treatment of Beh\u00e7et\u2019s disease","volume":"192","author":"Azizlerli","year":"1996","journal-title":"Dermatology"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB44","first-page":"313","article-title":"Erosive arthritis and posterior uveitis in Beh\u00e7et\u2019s disease","volume":"14","author":"K\u00f6tter","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB45","first-page":"285","article-title":"Alpha interferon in Beh\u00e7et\u2019s disease","volume":"9","author":"D\u00fcndar","year":"1996","journal-title":"Hematology Reviews"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB46","first-page":"559","article-title":"Systemic interferon-alfa in the treatment of Adamantiades-Beh\u00e7et\u2019s disease","volume":"63","author":"Zouboulis","year":"1996","journal-title":"Rev Rhum Engl Ed"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB47","first-page":"477","article-title":"L\u2019alfa interferone nella malattia di Beh\u00e7et","volume":"42","author":"Massaro","year":"1996","journal-title":"Riv Neurobiol"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB48","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1600-0420.1997.tb00638.x","article-title":"Interferon alpha for ocular Beh\u00e7et\u2019s disease","volume":"75","author":"Pivetti-Pezzi","year":"1997","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB49","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/S0140-6736(97)10114-3","article-title":"Loss of vision and diarrhoea","volume":"350","author":"Grimbacher","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB50","series-title":"The long-term treatment with interferon-alfa2a in Beh\u00e7et\u2019s Disease","author":"Hamza","year":"1997"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB51","series-title":"Seventh International Conference on Beh\u00e7et\u2019s Disease","article-title":"Alfa interferon therapy of ocular Beh\u00e7et\u2019s disease-related uveitis","author":"Hamza","year":"1997"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB52","first-page":"1938","article-title":"Interferon-alpha treatment of Beh\u00e7et\u2019s disease","volume":"25","author":"O\u2019Duffy","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB53","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1046\/j.1365-2796.1998.00159.x","article-title":"Efficacy and safety of systemic recombinant interferon-alpha in Beh\u00e7et\u2019s disease","volume":"243","author":"Georgiou","year":"1998","journal-title":"J Intern Med"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB54","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/bjo.82.5.488","article-title":"Treatment of ocular symptoms of Beh\u00e7et\u2019s disease with interferon alpha 2a","volume":"82","author":"K\u00f6tter","year":"1998","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB55","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1046\/j.1365-2141.1998.01038.x","article-title":"Reactivation of Beh\u00e7et\u2019s disease in the course of multicentric HHV8-positive Castleman\u2019s disease","volume":"103","author":"Strohal","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB56","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000018427","article-title":"Long-term effects of interferon alpha 2A treatment in Beh\u00e7et\u2019s disease","volume":"201","author":"Boyvat","year":"2000","journal-title":"Dermatology"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB57","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1136\/bjo.84.12.1432g","article-title":"Complete regression of retinal neovascularization after therapy with interferon alfa in Beh\u00e7et\u2019s disease","volume":"84","author":"Stuebiger","year":"2000","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB58","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1076\/ocii.8.4.293.6453","article-title":"Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Beh\u00e7et\u2019s disease","volume":"8","author":"Wechsler","year":"2000","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB59","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2169\/internalmedicine.39.667","article-title":"Beneficial effects of interferon-alpha in a case with Beh\u00e7et\u2019s disease","volume":"39","author":"Aoki","year":"2000","journal-title":"Intern Med"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB60","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0140-6736(99)05131-4","article-title":"Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Beh\u00e7et\u2019s disease","volume":"355","author":"Demiroglu","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB61","series-title":"Eighth and Ninth International Conference on Beh\u00e7et\u2019s Disease","article-title":"Treatment of severe uveitis of Beh\u00e7et\u2019s syndrome with the combination of interferon alfa 2b and azathioprine","author":"Bang","year":"2000"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB62","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/ard.60.1.83","article-title":"HHV8 associated Kaposi\u2019s sarcoma during triple immunosuppressive treatment with cyclosporin A, azathioprine, and prednisolone for ocular Beh\u00e7et\u2019s disease and complete remission of both disorders with interferon alpha","volume":"60","author":"K\u00f6tter","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB63","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1055\/s-2001-19687","article-title":"Beh\u00e7et\u2019s disease","volume":"528","author":"St\u00fcbiger","year":"2001","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB64","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00041327-200106000-00011","article-title":"Interferon-alpha 2a treatment of neuro-Beh\u00e7et disease","volume":"21","author":"Nichols","year":"2001","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB65","first-page":"43","article-title":"Adamantiadi-Beh\u00e7et syndrome","volume":"73","author":"Kacunaros","year":"2001","journal-title":"Ter Arkh"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB66","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.138.4.467","article-title":"Interferon alfa-2a in the treatment of Beh\u00e7et disease","volume":"138","author":"Alpsoy","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB67","series-title":"Treatment of ocular Adamantiades-Beh\u00e7et\u2019s disease with interferon-alfa. Tenth International Conference on Beh\u00e7et\u2019s Disease","year":"2002"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB68","series-title":"Efficacy and safety of interferon alfa-2a in intractable Beh\u00e7et\u2019s disease associated uveitis Tenth International Conference on Beh\u00e7et\u2019s Disease","year":"2002"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB69","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/S0140-6736(00)02811-7","article-title":"Retraction","volume":"356","author":"Horton","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB70","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/bjo.87.4.423","article-title":"Human recombinant interferon-alpha2a for the treatment of Beh\u00e7et\u2019s disease with sight-threatening posterior or panuveitis","volume":"87","author":"K\u00f6tter","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB71","first-page":"92","article-title":"Therapy of Beh\u00e7et\u2019s disease","volume":"5","author":"K\u00f6tter","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB72","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1346-8138.1999.tb03461.x","article-title":"Pityriasis rosea in a patient with Beh\u00e7et\u2019s disease treated with interferon alpha 2A","volume":"26","author":"Durusoy","year":"1999","journal-title":"J Dermatol"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB73","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0190-9622(99)70538-4","article-title":"Interferon alfa-2b-induced Meyerson\u2019s nevi in a patient with dysplastic nevus syndrome","volume":"40","author":"Krischer","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB74","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/archderm.134.8.1010","article-title":"Treatment of Adamantiades-Beh\u00e7et disease with systemic interferon alfa","volume":"134","author":"Zouboulis","year":"1998","journal-title":"Arch Dermatol"},{"issue":"Pt 2","key":"10.1016\/j.semarthrit.2003.09.010_BIB75","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/eye.1999.59","article-title":"Ocular complications with high-dose interferon alpha in chronic active hepatitis","volume":"13","author":"Kadayifcilar","year":"1999","journal-title":"Eye"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB76","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/hep.510270533","article-title":"Neurovisual impairment","volume":"27","author":"Manesis","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB77","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0168-8278(05)80331-9","article-title":"Optic tract neuropathy complicating low-dose interferon treatment","volume":"21","author":"Manesis","year":"1994","journal-title":"J Hepatol"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB78","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/rheumatology\/37.11.1148","article-title":"Skin hyperreactivity of Beh\u00e7et\u2019s patients (pathergy reaction) is also positive in interferon alpha-treated chronic myeloid leukaemia patients, indicating similarly altered neutrophil functions in both disorders","volume":"37","author":"Budak-Alpdogan","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB79","first-page":"45","article-title":"Beh\u00e7et\u2019s disease in patients with chronic myelogenous leukemia","volume":"74","author":"Budak-Alpdogan","year":"1997","journal-title":"Ann Hematol"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB80","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/10428199809068563","article-title":"The biology of interferon-alpha and the clinical significance of anti-interferon antibodies","volume":"29","author":"Hanley","year":"1998","journal-title":"Leukoc Lymphoma"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB81","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0033-3182(99)71208-9","article-title":"Neuropsychiatric toxicity associated with cytokine therapies","volume":"40","author":"Lerner","year":"1999","journal-title":"Psychosomatics"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB82","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0305-4179(98)00073-4","article-title":"Burns in a suicide attempt related to psychiatric side effects of interferon","volume":"24","author":"Fukunishi","year":"1998","journal-title":"Burns"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB83","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0167-5699(96)10027-X","article-title":"The neglected role of type I interferon in the T-cell response","volume":"17","author":"Belardelli","year":"1996","journal-title":"Immunol Today"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB84","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1359-6101(01)00022-3","article-title":"Interferon-alpha in tumor immunity and immunotherapy","volume":"13","author":"Belardelli","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB85","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/0145-2126(92)90047-B","article-title":"Immunological studies of gamma delta T cells in a case of large granular lymphocyte (LGL) leukemia","volume":"16","author":"Metzger","year":"1992","journal-title":"Leukoc Res"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB86","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1365-2249.1992.tb06470.x","article-title":"Interferon-alpha and dexamethasone inhibit adhesion of T cells to endothelial cells and synovial cells","volume":"88","author":"Eguchi","year":"1992","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.semarthrit.2003.09.010_BIB87","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/bio.606","article-title":"Effect of interferon-alpha on production of reactive oxygen species by human neutrophils","volume":"16","author":"Koie","year":"2001","journal-title":"Luminescence"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB88","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1006\/cyto.1999.0557","article-title":"Corticosteroids and interferons inhibit cytokine-induced production of IL-8 by human endothelial cells","volume":"12","author":"Nyhlen","year":"2000","journal-title":"Cytokine"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB89","first-page":"495","article-title":"Polymorphonuclear leukocyte myeloperoxidase levels in patients with Beh\u00e7et\u2019s disease","volume":"18","author":"Accardo-Palumbo","year":"2000","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB90","first-page":"126","article-title":"Natural killer cells in Beh\u00e7et\u2019s disease","volume":"71","author":"Hamzaoui","year":"1988","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB91","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000018426","article-title":"Adamantiades-Beh\u00e7et\u2019s disease","volume":"201","author":"Katsantonis","year":"2000","journal-title":"Dermatology"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB92","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s004030000128","article-title":"Adamantiades-Beh\u00e7et\u2019s disease","volume":"292","author":"Zouboulis","year":"2000","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB93","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/09629350220131935","article-title":"Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Beh\u00e7et\u2019s disease","volume":"11","author":"Evereklioglu","year":"2002","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.semarthrit.2003.09.010_BIB94","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1046\/j.1365-2249.1999.01069.x","article-title":"Gammadelta T cells in Beh\u00e7et\u2019s disease (BD) and recurrent aphthous stomatitis (RAS)","volume":"118","author":"Freysdottir","year":"1999","journal-title":"Clin Exp Immunol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017203001677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017203001677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T22:55:48Z","timestamp":1585695348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017203001677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":94,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["S0049017203001677"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2003.09.010","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}